Keywords: debiopharm, validates, htnfa, vacc, lausanne, switzerland-based, drugmaker
Debiopharm validates 0512 as hTNFa vacc
Article | 19 March 2007
Lausanne, Switzerland-based drugmaker Debiopharm presented preclinical data that validate the mechanism of action of Debio-0512, its potential treatment for cancer ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
